Pleiotropic Role of TRPV1 in Psoriasis Inflammation

NCT ID: NCT04848194

Last Updated: 2025-03-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-22
• Study Completion Date: 2024-01-24

Brief Summary

Widely expressed in the sensory nerve endings of the skin, Transient Receptor Potential Vanilloid 1 (TRPV1) is a receptor that plays an important role in the perception of pain and pruritus but also in skin inflammation, primarily by inducing the local release of several neuropeptides.

Although the mechanisms by which TRPV1-sensitizing inflammatory mediators in damaged skin have received considerable attention, the role of TRPV1 in psoriasis has so far been little explored.

However, two studies have reported that ablation of sensory nerves expressing TRPV1 reduced psoriasiform skin inflammation, demonstrating the neuronal contribution to inflammation in psoriasis.

However, the expression of TRPV1 is not limited to neurons alone. TRPV1 is also expressed by epidermal keratinocytes and skin microvessels.

For example, in 2018, transcriptomic analysis of psoriatic patient skins (by definition devoid of neuron nuclei) revealed that TRPV1 expression was increased in the skin of psoriatic patients suffering from itching (pruritus).

Regarding human keratinocytes, it is recognized that the activation of TRPV1 present on their surface induces the release of pro-inflammatory factors such as cyclooxygenase-2. In addition, the investigators have demonstrated that TRPV1 has a pivotal role in the keratinocyte production of inflammatory mediators, which is mediated by the protease-activated receptor-2 (PAR-2). However, the role of vascular TRPV1 in inflammation is not described.

The investigators hypothesize that in addition to neuronal TRPV1, non-neuronal TRPV1 receptors of non-neuronal cells (keratinocytes and endothelial cells) may be involved in the vicious circle of the inflammatory process characteristic of psoriasis. Putting TRPV1 at the center of the deregulation of the homeostatic balance including epithelial, neuronal and vascular inflammation in psoriasis is totally innovative.

Detailed Description

Each patient will have a sample taken in the dermatology department:

• 4 skin biopsies
• A blood sample.

Patients with psoriasis will be recruited from the dermatology department. There will be no further visits, so the duration of the study is 1 day.

The samples taken will be used to determine the pleiotropic role of TRPV1 in Psoriasis Inflammation.

Conditions

Inflammation; Skin; Psoriasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

All patients

All patients with psoriasis recruted by dermatological departement.

Group Type: OTHER

skin biopsy and blood sampling

Intervention Type: PROCEDURE

• 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.
• A blood sample

Interventions

skin biopsy and blood sampling

• 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.
• A blood sample

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patients over 18 years old with psoriasis, with or without itching (pruritus).
• Presence of lesional and non lesional zones, in unexposed areas and surface area (outside the face and folds) large enough to allow the biopsies to be performed
• Patients who have given written consent

Exclusion Criteria

• Patients with physical or psychological incapacity to sign consent
• Patients not covered by the Social Security system
• Patients with topical treatments for psoriasis,
• Patients with systemic treatments for psoriasis,
• Patients allergic to lidocaine
• Patients over the age of majority who are subject to legal protection or who are unable to give consent
• Patients deprived of liberty by a judicial or administrative decision
• Pregnant women, parturients and breastfeeding mothers

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Brest

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

TALAGAS

Brest, , France

Countries

France

Other Identifiers

29BRC21.0013

Identifier Type: -

Identifier Source: org_study_id